Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice. / Hansson, P; Jensen, Troels Staehelin; Kvarstein, G; Strömberg, M.

In: European journal of pain (London, England), Vol. 22, No. 5, 05.2018, p. 941-950.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Hansson, P ; Jensen, Troels Staehelin ; Kvarstein, G ; Strömberg, M. / Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice. In: European journal of pain (London, England). 2018 ; Vol. 22, No. 5. pp. 941-950.

Bibtex

@article{d8e144458f734c1c8eb03769d3b90bb5,
title = "Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8{\%} patch treatment of peripheral neuropathic pain in Scandinavian clinical practice",
abstract = "CONTEXT: Clinical trials have demonstrated the efficacy and safety of the capsaicin 8{\%} patch in patients with peripheral neuropathic pain (PNP); however, few studies have assessed this treatment in a clinical practice.OBJECTIVE: To determine whether treatment and re-treatment with the capsaicin 8{\%} patch reduce PNP intensity in clinical practice.METHODS: Three non-interventional, observational studies were concurrently conducted in Denmark, Norway and Sweden. Patients with probable or definite PNP received one or two treatments with the capsaicin 8{\%} patch according to usual clinical practice. All analyses were performed on combined data.RESULTS: Overall, 382 and 181 patients received treatment and re-treatment, respectively, with the capsaicin 8{\%} patch. At the group level, a significant reduction in mean level of 'usual pain' intensity (Numerical Pain Rating Scale) over the last 24 h' score was observed from baseline to Weeks 2 through 8 [-1.05 (95{\%} confidence interval: -1.27, 0.82); p < 0.001] with 28{\%} and 31{\%} of patients reporting a ≥30{\%} reduction in pain after first treatment and re-treatment, respectively. Improvements in health-related quality of life (EQ-5D-3L index) and overall health status (Patient Global Impression of Change) were observed early (Week 1) and throughout the treatment periods. Most application site reactions subsided within a week after treatment. Following treatment and re-treatment, 57{\%} and 71{\%} of patients, respectively, were willing to undergo further treatment with the capsaicin 8{\%} patch.CONCLUSION: In Scandinavian clinical practice, capsaicin 8{\%} patch treatment was associated with significant reductions in pain intensity and was well tolerated with over half of patients willing to undergo re-treatment.",
keywords = "Journal Article",
author = "P Hansson and Jensen, {Troels Staehelin} and G Kvarstein and M Str{\"o}mberg",
note = "{\circledC} 2018 European Pain Federation - EFIC{\circledR}.",
year = "2018",
month = "5",
doi = "10.1002/ejp.1180",
language = "English",
volume = "22",
pages = "941--950",
journal = "European Journal of Pain",
issn = "1090-3801",
publisher = "JohnWiley & Sons Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice

AU - Hansson, P

AU - Jensen, Troels Staehelin

AU - Kvarstein, G

AU - Strömberg, M

N1 - © 2018 European Pain Federation - EFIC®.

PY - 2018/5

Y1 - 2018/5

N2 - CONTEXT: Clinical trials have demonstrated the efficacy and safety of the capsaicin 8% patch in patients with peripheral neuropathic pain (PNP); however, few studies have assessed this treatment in a clinical practice.OBJECTIVE: To determine whether treatment and re-treatment with the capsaicin 8% patch reduce PNP intensity in clinical practice.METHODS: Three non-interventional, observational studies were concurrently conducted in Denmark, Norway and Sweden. Patients with probable or definite PNP received one or two treatments with the capsaicin 8% patch according to usual clinical practice. All analyses were performed on combined data.RESULTS: Overall, 382 and 181 patients received treatment and re-treatment, respectively, with the capsaicin 8% patch. At the group level, a significant reduction in mean level of 'usual pain' intensity (Numerical Pain Rating Scale) over the last 24 h' score was observed from baseline to Weeks 2 through 8 [-1.05 (95% confidence interval: -1.27, 0.82); p < 0.001] with 28% and 31% of patients reporting a ≥30% reduction in pain after first treatment and re-treatment, respectively. Improvements in health-related quality of life (EQ-5D-3L index) and overall health status (Patient Global Impression of Change) were observed early (Week 1) and throughout the treatment periods. Most application site reactions subsided within a week after treatment. Following treatment and re-treatment, 57% and 71% of patients, respectively, were willing to undergo further treatment with the capsaicin 8% patch.CONCLUSION: In Scandinavian clinical practice, capsaicin 8% patch treatment was associated with significant reductions in pain intensity and was well tolerated with over half of patients willing to undergo re-treatment.

AB - CONTEXT: Clinical trials have demonstrated the efficacy and safety of the capsaicin 8% patch in patients with peripheral neuropathic pain (PNP); however, few studies have assessed this treatment in a clinical practice.OBJECTIVE: To determine whether treatment and re-treatment with the capsaicin 8% patch reduce PNP intensity in clinical practice.METHODS: Three non-interventional, observational studies were concurrently conducted in Denmark, Norway and Sweden. Patients with probable or definite PNP received one or two treatments with the capsaicin 8% patch according to usual clinical practice. All analyses were performed on combined data.RESULTS: Overall, 382 and 181 patients received treatment and re-treatment, respectively, with the capsaicin 8% patch. At the group level, a significant reduction in mean level of 'usual pain' intensity (Numerical Pain Rating Scale) over the last 24 h' score was observed from baseline to Weeks 2 through 8 [-1.05 (95% confidence interval: -1.27, 0.82); p < 0.001] with 28% and 31% of patients reporting a ≥30% reduction in pain after first treatment and re-treatment, respectively. Improvements in health-related quality of life (EQ-5D-3L index) and overall health status (Patient Global Impression of Change) were observed early (Week 1) and throughout the treatment periods. Most application site reactions subsided within a week after treatment. Following treatment and re-treatment, 57% and 71% of patients, respectively, were willing to undergo further treatment with the capsaicin 8% patch.CONCLUSION: In Scandinavian clinical practice, capsaicin 8% patch treatment was associated with significant reductions in pain intensity and was well tolerated with over half of patients willing to undergo re-treatment.

KW - Journal Article

U2 - 10.1002/ejp.1180

DO - 10.1002/ejp.1180

M3 - Journal article

VL - 22

SP - 941

EP - 950

JO - European Journal of Pain

JF - European Journal of Pain

SN - 1090-3801

IS - 5

ER -